1
|
Middlebrooks EH, Szaflarski JP, Begnaud J, Thaker A, Henderson K, Bolding M, Sellers JA, Allendorfer J. Compatibility of Standard Vagus Nerve Stimulation and Investigational Microburst Vagus Nerve Stimulation Therapy with fMRI. AJNR Am J Neuroradiol 2024:ajnr.A8235. [PMID: 38448165 DOI: 10.3174/ajnr.a8235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Accepted: 03/05/2024] [Indexed: 03/08/2024]
Abstract
Vagus nerve stimulation devices are conditionally approved for MR imaging with stimulation turned off, and the requirement to modify the stimulation settings may be a barrier to scanning in some radiology practices. There is increasing interest in studying the effects of stimulation during MR imaging/fMRI. This study evaluated the safety of standard and investigational microburst vagus nerve stimulation therapies during MR imaging/fMRI. A prospective, multicenter study was conducted in patients with an investigational vagus nerve stimulation device that delivered either standard or investigational microburst vagus nerve stimulation. Thirty participants underwent sequential MR imaging and fMRI scans, encompassing 188 total hours of scan time (62.7 hours with standard vagus nerve stimulation and 125.3 hours with investigational microburst vagus nerve stimulation). No adverse events were reported with active stimulation during MR imaging or during 12 months of follow-up. Our results support the safety of standard and investigational microburst vagus nerve stimulation therapy during MR imaging and fMRI scans.
Collapse
Affiliation(s)
- Erik H Middlebrooks
- From the Department of Neuroradiology (E.H.M.), Mayo Clinic College of Medicine and Science, Jacksonville, Florida
| | - Jerzy P Szaflarski
- Department of Neurology (J.P.S., M.B., J.A.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
| | - Jason Begnaud
- Neuromodulation Division (J.B., K.H.), LivaNova USA, Houston, Texas
| | - Ashesh Thaker
- Departmentd of Neuroradiology (A.T.) and Radiology, Denver Health, University of Colorado School of Medicine, Denver, Colorado
| | - Kenny Henderson
- Neuromodulation Division (J.B., K.H.), LivaNova USA, Houston, Texas
| | - Mark Bolding
- Department of Neurology (J.P.S., M.B., J.A.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
| | - Jill A Sellers
- Sellers Communications LLC (J.A.S.), Springfield, Missouri
| | - Jane Allendorfer
- Department of Neurology (J.P.S., M.B., J.A.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
2
|
Grigoriadou S, Clubbe R, Garcez T, Huissoon A, Grosse-Kreul D, Jolles S, Henderson K, Edmonds J, Lowe D, Bethune C. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy. Clin Exp Immunol 2022; 210:1-13. [PMID: 35924867 PMCID: PMC9585546 DOI: 10.1093/cei/uxac070] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Revised: 04/08/2022] [Accepted: 08/03/2022] [Indexed: 01/25/2023] Open
Abstract
Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care.
Collapse
Affiliation(s)
- S Grigoriadou
- Department of Immunology, Royal London Hospital, Barts Health NHS Trust, London, UK
| | - R Clubbe
- National Guideline Centre, Royal College of Physicians, London, UK
| | - T Garcez
- Immunology Department, Manchester University NHS Trust, Manchester, UK
| | - A Huissoon
- West Midlands Immunodeficiency Centre, Birmingham Heartlands Hospital, Birmingham, UK
| | - D Grosse-Kreul
- Department of Immunological Medicine, King’s College Hospital, London, UK
| | - S Jolles
- Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK
| | - K Henderson
- Immunology Department, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - J Edmonds
- Immunology Department, Manchester University NHS Trust, Manchester, UK
| | - D Lowe
- UCL Institute of Immunity and Transplantation, Royal Free Hospital, London, UK
| | - C Bethune
- Peninsula Immunology and Allergy Service, University Hospitals Plymouth, Plymouth, UK
| |
Collapse
|
3
|
Uflacker A, Keefe N, Bruner E, Avery A, Salzar R, Henderson K, Spratley M, Nacey N, Miller W, Chahin J, Grewal S, Safavian D, Haskal Z. Abstract No. 348 ▪ FEATURED ABSTRACT Assessing effects of geniculate artery embolization in a non-surgical animal model of osteoarthritis. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Henderson K, Cassels-Barker A, Edwards Z. P.196 A cerebral confusion; spontaneous subarachnoid haemorrhage in labour. Int J Obstet Anesth 2022. [DOI: 10.1016/j.ijoa.2022.103492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Cardenas T, Murphy TJ, Kuettner L, Patterson B, Goodwin L, Cluff K, Oertel J, Day T, Edwards S, Hamilton CE, Randolph R, Henderson K, Cowan J, Shin SJ, Bhandarkar S, Kozioziemski BJ. Material Characterization of Hierarchical Tunable Pore Size Polymer Foams Used in the MARBLE Mix Morphology Experiment. Fusion Science and Technology 2020. [DOI: 10.1080/15361055.2020.1790713] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- T. Cardenas
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - T. J. Murphy
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - L. Kuettner
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - B. Patterson
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - L. Goodwin
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - K. Cluff
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - J. Oertel
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - T. Day
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - S. Edwards
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - C. E. Hamilton
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - R. Randolph
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - K. Henderson
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - J. Cowan
- Los Alamos National Laboratory, SM30 Bikini Atoll Road, Los Alamos, New Mexico 87545
| | - S. J. Shin
- Lawrence Livermore National Laboratory, Livermore, California
| | - S. Bhandarkar
- Lawrence Livermore National Laboratory, Livermore, California
| | | |
Collapse
|
6
|
Mawer D, Byrne F, Drake S, Brown C, Prescott A, Warne B, Bousfield R, Skittrall JP, Ramsay I, Somasunderam D, Bevan M, Coslett J, Rao J, Stanley P, Kennedy A, Dobson R, Long S, Obisanya T, Esmailji T, Petridou C, Saeed K, Brechany K, Davis-Blue K, O'Horan H, Wake B, Martin J, Featherstone J, Hall C, Allen J, Johnson G, Hornigold C, Amir N, Henderson K, McClements C, Liew I, Deshpande A, Vink E, Trigg D, Guilfoyle J, Scarborough M, Scarborough C, Wong THN, Walker T, Fawcett N, Morris G, Tomlin K, Grix C, O'Cofaigh E, McCaffrey D, Cooper M, Corbett K, French K, Harper S, Hayward C, Reid M, Whatley V, Winfield J, Hoque S, Kelly L, King I, Bradley A, McCullagh B, Hibberd C, Merron M, McCabe C, Horridge S, Taylor J, Koo S, Elsanousi F, Saunders R, Lim F, Bond A, Stone S, Milligan ID, Mack DJF, Nagar A, West RM, Wilcox MH, Kirby A, Sandoe JAT. Cross-sectional study of the prevalence, causes and management of hospital-onset diarrhoea. J Hosp Infect 2019; 103:200-209. [PMID: 31077777 DOI: 10.1016/j.jhin.2019.05.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Accepted: 05/01/2019] [Indexed: 11/25/2022]
Abstract
BACKGROUND The National Health Service in England advises hospitals collect data on hospital-onset diarrhoea (HOD). Contemporaneous data on HOD are lacking. AIM To investigate prevalence, aetiology and management of HOD on medical, surgical and elderly-care wards. METHODS A cross-sectional study in a volunteer sample of UK hospitals, which collected data on one winter and one summer day in 2016. Patients admitted ≥72 h were screened for HOD (definition: ≥2 episodes of Bristol Stool Type 5-7 the day before the study, with diarrhoea onset >48 h after admission). Data on HOD aetiology and management were collected prospectively. FINDINGS Data were collected on 141 wards in 32 hospitals (16 acute, 16 teaching). Point-prevalence of HOD was 4.5% (230/5142 patients; 95% confidence interval (CI) 3.9-5.0%). Teaching hospital HOD prevalence (5.9%, 95% CI 5.1-6.9%) was twice that of acute hospitals (2.8%, 95% CI 2.1-3.5%; odds ratio 2.2, 95% CI 1.7-3.0). At least one potential cause was identified in 222/230 patients (97%): 107 (47%) had a relevant underlying condition, 125 (54%) were taking antimicrobials, and 195 (85%) other medication known to cause diarrhoea. Nine of 75 tested patients were Clostridium difficile toxin positive (4%). Eighty (35%) patients had a documented medical assessment of diarrhoea. Documentation of HOD in medical notes correlated with testing for C. difficile (78% of those tested vs 38% not tested, P<0.001). One-hundred and forty-four (63%) patients were not isolated following diarrhoea onset. CONCLUSION HOD is a prevalent symptom affecting thousands of patients across the UK health system each day. Most patients had multiple potential causes of HOD, mainly iatrogenic, but only a third had medical assessment. Most were not tested for C. difficile and were not isolated.
Collapse
Affiliation(s)
- D Mawer
- Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK.
| | - F Byrne
- Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK
| | - S Drake
- Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK
| | - C Brown
- Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK
| | - A Prescott
- Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK
| | - B Warne
- Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - R Bousfield
- Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - J P Skittrall
- Royal Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, CB23 3RE, UK
| | - I Ramsay
- Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - D Somasunderam
- Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - M Bevan
- Department of Infection Prevention, Royal Gwent Hospital, Newport, NP20 2UB, UK
| | - J Coslett
- Department of Infection Prevention, Royal Gwent Hospital, Newport, NP20 2UB, UK
| | - J Rao
- Department of Microbiology, Barnsley Hospital NHS Foundation Trust, Barnsley, S75 2EP, UK
| | - P Stanley
- Infection Prevention and Control, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK
| | - A Kennedy
- Infection Prevention and Control, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK
| | - R Dobson
- Infection Prevention and Control, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK
| | - S Long
- Department of Microbiology, East Lancashire Hospitals NHS Trust, Blackburn, BB2 3HH, UK
| | - T Obisanya
- Department of Microbiology, East Lancashire Hospitals NHS Trust, Blackburn, BB2 3HH, UK
| | - T Esmailji
- Department of Microbiology, East Lancashire Hospitals NHS Trust, Blackburn, BB2 3HH, UK
| | - C Petridou
- Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Winchester, SO22 5DG, UK
| | - K Saeed
- Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Winchester, SO22 5DG, UK
| | - K Brechany
- Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Winchester, SO22 5DG, UK
| | - K Davis-Blue
- Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Winchester, SO22 5DG, UK
| | - H O'Horan
- Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Winchester, SO22 5DG, UK
| | - B Wake
- Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Winchester, SO22 5DG, UK
| | - J Martin
- Department of Microbiology, Harrogate and District NHS Foundation Trust, Harrogate, HG2 7SX, UK
| | - J Featherstone
- Department of Microbiology, Harrogate and District NHS Foundation Trust, Harrogate, HG2 7SX, UK
| | - C Hall
- Department of Infectious Diseases, Hull and East Yorkshire Hospitals NHS Trust, Hull, HU3 2JZ, UK
| | - J Allen
- Department of Infectious Diseases, Hull and East Yorkshire Hospitals NHS Trust, Hull, HU3 2JZ, UK
| | - G Johnson
- Department of Infectious Diseases, Hull and East Yorkshire Hospitals NHS Trust, Hull, HU3 2JZ, UK
| | - C Hornigold
- Department of Infectious Diseases, Hull and East Yorkshire Hospitals NHS Trust, Hull, HU3 2JZ, UK
| | - N Amir
- Department of Microbiology, Mid Yorkshire Hospitals NHS Trust, Wakefield, WF1 4DG, UK
| | - K Henderson
- Inverclyde Royal Hospital, Greenock, PA16 0XN, UK
| | - C McClements
- Inverclyde Royal Hospital, Greenock, PA16 0XN, UK
| | - I Liew
- Inverclyde Royal Hospital, Greenock, PA16 0XN, UK
| | - A Deshpande
- Department of Microbiology, Inverclyde Royal Hospital, Greenock, PA16 0XN, UK
| | - E Vink
- Department of Microbiology, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, UK
| | - D Trigg
- Department of Infection Prevention & Control, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, UK
| | - J Guilfoyle
- Department of Infection Prevention & Control, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, UK
| | - M Scarborough
- Department of Infectious Diseases, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, UK
| | - C Scarborough
- Nuffield Department of Medicine, University of Oxford, OX3 7FZ, UK
| | - T H N Wong
- Department of Infectious Diseases, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, UK
| | - T Walker
- Department of Infectious Diseases, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, UK
| | - N Fawcett
- Department of Medicine, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, UK
| | - G Morris
- Department of Microbiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK
| | - K Tomlin
- Department of Infection Prevention & Control, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK
| | - C Grix
- Department of Infection Prevention & Control, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK
| | - E O'Cofaigh
- Department of Medicine, Friarage Hospital, South Tees Hospital NHS Foundation Trust, Northallerton, DL6 1JG, UK
| | - D McCaffrey
- Department of Infection Prevention & Control, James Cook University Hospital, South Tees Hospital NHS Foundation Trust, Middlesborough, TS4 3BW, UK
| | - M Cooper
- Department of Microbiology, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - K Corbett
- Department of Infection Prevention & Control, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - K French
- Department of Microbiology, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - S Harper
- Department of Infection Prevention & Control, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - C Hayward
- Department of Infection Prevention & Control, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - M Reid
- Department of Infection Prevention & Control, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - V Whatley
- Corporate Support Services, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - J Winfield
- Department of Infection Prevention & Control, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, UK
| | - S Hoque
- Department of Microbiology, Torbay and South Devon Healthcare NHS Foundation Trust, Torquay, TQ2 7AA, UK
| | - L Kelly
- Department of Infection Prevention & Control, Torbay and South Devon Healthcare NHS Foundation Trust, Torquay, TQ2 7AA, UK
| | - I King
- Department of Infection Prevention & Control, Ulster Hospital, South Eastern Health and Social Care Trust, Belfast, BT16 1RH, UK
| | - A Bradley
- Department of Infection Prevention & Control, Ulster Hospital, South Eastern Health and Social Care Trust, Belfast, BT16 1RH, UK
| | - B McCullagh
- Pharmacy Department, Ulster Hospital, South Eastern Health and Social Care Trust, Belfast, BT16 1RH, UK
| | - C Hibberd
- Pharmacy Department, Ulster Hospital, South Eastern Health and Social Care Trust, Belfast, BT16 1RH, UK
| | - M Merron
- Department of Infection Prevention & Control, Ulster Hospital, South Eastern Health and Social Care Trust, Belfast, BT16 1RH, UK
| | - C McCabe
- Department of Infection Prevention & Control, Ulster Hospital, South Eastern Health and Social Care Trust, Belfast, BT16 1RH, UK
| | - S Horridge
- Department of Microbiology, University Hospital Coventry, University Hospitals of Coventry and Warwickshire, Warwick, CV2 2DX, UK
| | - J Taylor
- Department of Virology and Molecular Pathology, University Hospital Coventry, University Hospitals of Coventry and Warwickshire, Warwick, CV2 2DX, UK
| | - S Koo
- Department of Microbiology, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, UK
| | - F Elsanousi
- Department of Microbiology, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, UK
| | - R Saunders
- Department of Microbiology, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, UK
| | - F Lim
- Department of Microbiology, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, UK
| | - A Bond
- Department of Microbiology, York Teaching Hospital NHS Foundation Trust, York, YO31 8HE, UK
| | - S Stone
- Royal Free Campus, University College Medical School, London, NW3 2QG, UK
| | - I D Milligan
- Department of Microbiology, Royal Free Hospital, University College London Hospitals NHS Foundation Trust, London, NW3 2QG, UK
| | - D J F Mack
- Department of Microbiology, Royal Free Hospital, University College London Hospitals NHS Foundation Trust, London, NW3 2QG, UK
| | - A Nagar
- Department of Microbiology, Antrim Area Hospital, Northern Health and Social Care Trust, Bush Road, Antrim, BT41 2RL, UK
| | - R M West
- Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9JT, UK
| | - M H Wilcox
- Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, LS2 9JT, UK
| | - A Kirby
- Leeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK
| | - J A T Sandoe
- Leeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK
| |
Collapse
|
7
|
Henderson K, Barros C, Brum J, Sena N, Dias L, Cota R. Surgycal treatment of unicystic ameloblastoma of the mandible and root canal filling using mta in association with parendodontic surgery. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Henderson K, Paes M, Lima H, Pimenta R. Kissing molars – case report. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Cota R, Lucamba A, Henderson K. Third ectopic molar in orbit floor with associated dentigerous cyst. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Henderson K, L.Dias, Goto A, Menezes F, Cota R. Rapid maxillary expansion with supported bone palatal distractor - case report. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Henderson K, Dias L, Goto A, Menezes F, Cota R. Complex fractures of the midface with submental intubation - case report. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Uflacker A, Keefe N, Salzar R, Henderson K, Spratley E, Nacey N, David B, Whitehair R, Chahin J, Safavian D, Neiderer J, Stone J, Wick M, Cui Q, Haskal Z. Abstract No. 613 Intraarticular sodium monoiodoacetate injection induced osteoarthritis in sheep: a non-surgical large animal model for geniculate artery embolization. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
13
|
Sterling S, Jones A, King M, Galli R, Isom K, Summers R, Henderson K. 245 The Impact of the TelEmergency Program on Rural Emergency Care: An Implementation Study. Ann Emerg Med 2016. [DOI: 10.1016/j.annemergmed.2016.08.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Abstract
Introduction In England, emergency readmissions within 30 days of hospital discharge after an elective admission are not reimbursed if they do not meet Payment by Results (PbR) exclusion criteria. However, coding errors could inappropriately penalise hospitals. We aimed to assess the accuracy of coding for emergency readmissions. Methods Emergency readmissions attributed to paediatric surgery and urology between September 2012 and August 2014 to our tertiary referral centre were retrospectively reviewed. Payment by Results (PbR) coding data were obtained from the hospital's Family Health Directorate. Clinical details were obtained from contemporaneous records. All readmissions were categorised as appropriately coded (postoperative or nonoperative) or inappropriately coded (planned surgical readmission, unrelated surgical admission, unrelated medical admission or coding error). Results Over the 24-month period, 241 patients were coded as 30-day readmissions, with 143 (59%) meeting the PbR exclusion criteria. Of the remaining 98 (41%) patients, 24 (25%) were inappropriately coded as emergency readmissions. These readmissions resulted in 352 extra bed days, of which 117 (33%) were attributable to inappropriately coded cases. Conclusions One-quarter of non-excluded emergency readmissions were inappropriately coded, accounting for one-third of additional bed days. As a stay on a paediatric ward costs up to £500 a day, the potential cost to our institution due to inappropriate readmission coding was over £50,000. Diagnoses and the reason for admission for each care episode should be accurately documented and coded, and readmission data should be reviewed at a senior clinician level.
Collapse
Affiliation(s)
- R Peeraully
- Queen's Medical Centre, Nottingham University Hospitals NHS Trust , UK
| | - K Henderson
- Queen's Medical Centre, Nottingham University Hospitals NHS Trust , UK
| | - B Davies
- Queen's Medical Centre, Nottingham University Hospitals NHS Trust , UK
| |
Collapse
|
15
|
Hawk M, Vinci T, Henderson K, Roche B, Ritchie G, Behringer S, Knostman K. Blood pressure, heart rate, temperature, and central nervous system evaluation of cyanide intoxication in juvenile and adult mice. J Pharmacol Toxicol Methods 2015. [DOI: 10.1016/j.vascn.2015.08.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Henderson K, Henman S, Shearing V, Allen R, Blatch J, Johnson C. WS05.1 The development of a website to facilitate transition from paediatric to adult CF services. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30027-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Bolton S, Moore A, Henderson K. 108: Can a patient/carer information and support group address the unmet needs of people affected by mesothelioma? Lung Cancer 2015. [DOI: 10.1016/s0169-5002(15)50103-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Edgar JDM, Buckland M, Guzman D, Conlon NP, Knerr V, Bangs C, Reiser V, Panahloo Z, Workman S, Slatter M, Gennery AR, Davies EG, Allwood Z, Arkwright PD, Helbert M, Longhurst HJ, Grigoriadou S, Devlin LA, Huissoon A, Krishna MT, Hackett S, Kumararatne DS, Condliffe AM, Baxendale H, Henderson K, Bethune C, Symons C, Wood P, Ford K, Patel S, Jain R, Jolles S, El-Shanawany T, Alachkar H, Herwadkar A, Sargur R, Shrimpton A, Hayman G, Abuzakouk M, Spickett G, Darroch CJ, Paulus S, Marshall SE, McDermott EM, Heath PT, Herriot R, Noorani S, Turner M, Khan S, Grimbacher B. The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012. Clin Exp Immunol 2014; 175:68-78. [PMID: 23841717 PMCID: PMC3898556 DOI: 10.1111/cei.12172] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/04/2013] [Indexed: 12/11/2022] Open
Abstract
This report summarizes the establishment of the first national online registry of primary immune deficency in the United Kingdom, the United Kingdom Primary Immunodeficiency (UKPID Registry). This UKPID Registry is based on the European Society for Immune Deficiency (ESID) registry platform, hosted on servers at the Royal Free site of University College, London. It is accessible to users through the website of the United Kingdom Primary Immunodeficiency Network (www.ukpin.org.uk). Twenty-seven centres in the United Kingdom are actively contributing data, with an additional nine centres completing their ethical and governance approvals to participate. This indicates that 36 of 38 (95%) of recognized centres in the United Kingdom have engaged with this project. To date, 2229 patients have been enrolled, with a notable increasing rate of recruitment in the past 12 months. Data are presented on the range of diagnoses recorded, estimated minimum disease prevalence, geographical distribution of patients across the United Kingdom, age at presentation, diagnostic delay, treatment modalities used and evidence of their monitoring and effectiveness.
Collapse
Affiliation(s)
- J D M Edgar
- Regional Immunology Service, The Royal Hospitals, Belfast, East Yorkshire; Centre for Infection and Immunity, Queen's University Belfast, Belfast, East Yorkshire
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Manspeaker SA, Henderson K, Riddle JD. Treatment of exertional rhabdomyolysis in the athletic population: a systematic review. INT J EVID-BASED HEA 2013. [DOI: 10.1097/01258363-201309000-00049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Cozens JA, Jackson T, Henderson K, Brough S, Bhakta B, Makower SG, van Wijck F, Smith C. A framework to aid adoption of automated rehabilitation devices into clinical practice: synthesising and Interpreting Language for Clinical Kinematics (SILCK). IEEE Int Conf Rehabil Robot 2013; 2013:6650403. [PMID: 24187222 DOI: 10.1109/icorr.2013.6650403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The Synthesising and Interpreting Language for Clinical Kinematics (SILCK) is an informatic framework for developing software to control automated rehabilitation devices. It aids adoption of devices into rehabilitation practice, by bridging the gap between clinical practice and internal device operation. SILCK defines data entities and processes for capturing clinical observations of patients and their rehabilitation goals in formats which can be used to direct the tailoring of device parameters to the individual patient's needs.
Collapse
|
21
|
Kruper L, Xu XX, Bernstein L, Henderson K. Abstract PD08-02: Disparities in the Utilization of Reconstruction after Mastectomy: The California Teachers Study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd08-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: For breast cancer patients undergoing mastectomy, factors such as insurance status, race/ethnicity, age, and type of hospital influence whether post-mastectomy reconstruction (PMR) is performed. This study was undertaken to determine if additional patient variables and clinicopathologic features also influence the utilization of PMR using the California Teachers Study (CTS).
Methods: Patients were identified from the CTS, a cohort of approximately 133,000 female public school teachers and administrators, followed prospectively from 1995 forward to investigate exposures associated with incident cancer and other outcomes. All in situ and invasive breast cancers were identified through linkage with the California Cancer Registry, as well as with the California Office of Statewide Health Planning and Development (OSHPD) hospital discharge database to determine the rates of mastectomy with and without reconstruction. Patterns in PMR rates were examined by calendar year, age, race/ethnicity, type of insurance, type of hospital, tumor stage, body mass index (BMI), family history of breast cancer (FH), smoking history, physical activity, and prior breast implant status using a chi-square test. Univariable and multivariable-adjusted odds ratios (OR) with 95% confidence intervals (CI) were estimated for relative odds of immediate reconstruction vs. mastectomy only.
Results: During follow-up, 1,253 CTS participants with incident breast cancer underwent mastectomy with (N = 368) and without (N = 885) reconstruction. In multivariable stepwise logistic regression analyses, calendar year, age, type of insurance, tumor stage, and prior breast implant were statistically significantly associated with use of reconstruction. The proportion of patients undergoing immediate PMR increased from 21.8% during 1995–1999 to 26.4% during 2005–2009. A statistically significant dose-response was apparent between older age at surgery and decreased likelihood of post-mastectomy reconstruction (Ptrend<0.001). Race/ethnicity was not significantly associated with the use of PMR because the majority of patients were non-Hispanic white (89.5%). Most participants either had private insurance (56.8%) or Medicare (42.4%); those with private insurance were twice as likely to undergo PMR compared to patients with Medicare (OR 2.23: 95%CI 1.25–4.00, p = 0.01). Compared to participants with in situ and stage I breast cancer combined, participants with stage II or stage III breast cancer had one-third to one-half lower odds of postmastectomy reconstruction relative to mastectomy only (ORstageII = 0.67, 95% CI = 0.49–0.90, p = 0.01; ORstageIII=0.47, 95% CI=0.29–0.77, p = 0.002). Participants with a prior history of a breast implant were 7 times more likely to undergo PMR than participants with no such history (OR 7.14: 95%CI 2.38–21.41, p < 0.001).
Conclusions: In the CTS population, having a prior breast implant and lower tumor stage were additional variables associated with increased odds of PMR. This study validates previous studies which have shown that private insurance and younger age are associated with the use of reconstruction after mastectomy. Patient and health care provider education is warranted to ensure that all patients undergoing mastectomy are offered and have access to PMR.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD08-02.
Collapse
Affiliation(s)
- L Kruper
- City of Hope Cancer Center, Duarte, CA
| | - XX Xu
- City of Hope Cancer Center, Duarte, CA
| | | | | |
Collapse
|
22
|
Suh E, Ramsay M, Mandal S, Boleat E, Christian B, Henderson K, Murphy P, Moxham J, Hart N. S116 Parasternal muscle electromyelography (EMGpara) reflects observed changes in dynamic hyperinflation during acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Thorax 2011. [DOI: 10.1136/thoraxjnl-2011-201054b.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Henderson K, Shirgaonkar A, Vipond A, Easaw B. Labour analgesia and the baby: good news is no news. Int J Obstet Anesth 2011; 20:267. [PMID: 21640580 DOI: 10.1016/j.ijoa.2011.03.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2011] [Revised: 03/24/2011] [Accepted: 03/29/2011] [Indexed: 11/29/2022]
|
24
|
Cumin D, Weller J, Henderson K, Merry A. Standards for simulation in anaesthesia: creating confidence in the tools. Br J Anaesth 2010; 105:45-51. [DOI: 10.1093/bja/aeq095] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Newton A, Sarker SJ, Parfitt A, Henderson K, Jaye P, Drake N. Individual care plans can reduce hospital admission rate for patients who frequently attend the emergency department. Emerg Med J 2010; 28:654-7. [DOI: 10.1136/emj.2009.085704] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
|
27
|
Arici M, Reiner E, Kirsch J, Mojibian H, Pollak J, Henderson K, Weiss R, White R. Abstract No. 205: Results of varicocele embolization using sotradecol foam and fibered coils. J Vasc Interv Radiol 2010. [DOI: 10.1016/j.jvir.2009.12.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
28
|
Henderson K, Hiley T, Bell N, Armitage J. Patient evaluation and experience of a lung cancer support group. Lung Cancer 2010. [DOI: 10.1016/s0169-5002(10)70079-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
29
|
Taegtmeyer M, Hightower A, Opiyo W, Mwachiro L, Henderson K, Angala P, Ngare C, Marum E. A peer-led HIV counselling and testing programme for the deaf in Kenya. Disabil Rehabil 2009; 31:508-14. [DOI: 10.1080/09638280802133115] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Norris ML, Spettigue W, Buchholz A, Henderson K, Gomez R, Harrison M. Dyslipidemia Independent of Body Mass in Antipsychotic Treated Patients with Anorexia Nervosa. Paediatr Child Health 2009. [DOI: 10.1093/pch/14.suppl_a.15ab] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Henderson K, Worth H, Aggleton P, Kippax S. Enhancing HIV prevention requires addressing the complex relationship between prevention and treatment. Glob Public Health 2009; 4:117-30. [DOI: 10.1080/17441690802191329] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Lu Y, Sullivan-Halley J, Cozen W, Chang ET, Henderson K, Ma H, Deapen D, Clarke C, Reynolds P, Neuhausen SL, Anton-Culver H, Ursin G, West D, Bernstein L. Family history of haematopoietic malignancies and non-Hodgkin's lymphoma risk in the California Teachers Study. Br J Cancer 2009; 100:524-6. [PMID: 19156148 PMCID: PMC2658543 DOI: 10.1038/sj.bjc.6604881] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Family history of haematopoietic malignancies appears to be a risk factor for non-Hodgkin's lymphoma (NHL), but whether risk varies by family member's gender is unclear. Among 121 216 women participating in the prospective California Teachers Study, NHL risk varied by type of haematopoietic malignancy and gender of the relative.
Collapse
Affiliation(s)
- Y Lu
- Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center NOR-3429, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089-9175, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Bolton S, Borthwick D, Bell N, Wibberley G, Henderson K, Warner K, Horne N, Borgen P. Developing a guideline to enable lung cancer nurse specialists to consistently communicate key MDT decisions to patients. Lung Cancer 2009. [DOI: 10.1016/s0169-5002(09)70096-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Henderson K, Akhtar S, Sandoval M, Siddiqui S, Todd K, Wirtner A. 399: Femoral Nerve Block for Pain Management of Hip Fractures in the Emergency Department: Preliminary Results of a Randomized, Controlled Trial. Ann Emerg Med 2008. [DOI: 10.1016/j.annemergmed.2008.06.426] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Henderson K, Salis P, Caruso S, Chiaramonte G, Artero M. Unanticipated discovery of vascular anomalies by hemodialysis catheter placement. Case report. Minerva Anestesiol 2008; 74:209-211. [PMID: 18414364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
This case report describes an unexpected finding post hemodialysis catheter placement in a child scheduled for living-relation renal transplant. Moreover, the unusual appearance of the catheter on a chest X-ray prompted further investigation of the patient's vascular anatomy, resulting in the discovery of an aberrant iliac artery course that significantly affected the surgical approach to this planned procedure.
Collapse
Affiliation(s)
- K Henderson
- Department of Anesthesiology and Critical Care Medicine, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy.
| | | | | | | | | |
Collapse
|
36
|
Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22:1044-52. [PMID: 18216867 DOI: 10.1038/leu.2008.4] [Citation(s) in RCA: 215] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We report here the genetic aberrations and survival of 80 patients with pPCL or sPCL and make comparisons with 439 cases of MM. pPCL presents a decade earlier than sPCL (54.7 vs 65.3 years) and is associated with longer median overall survival (11.1 vs 1.3 months; P<0.001). 14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87%); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM. Both show ubiquitous inactivation of TP53 (pPCL 56%; sPCL 83%) by coding mutation or 17p13 deletion; complemented by p14ARF epigenetic silencing in sPCL (29%). Both show frequent N-RAS or K-RAS mutation. Poor survival in pPCL was predicted by MYC translocation (P=0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival.
Collapse
Affiliation(s)
- R E Tiedemann
- Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
|
38
|
Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21:582-4. [PMID: 17215851 DOI: 10.1038/sj.leu.2404524] [Citation(s) in RCA: 120] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
39
|
Chng WJ, Santana-Dávila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20:807-13. [PMID: 16511510 DOI: 10.1038/sj.leu.2404172] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Chromosomal hyperdiploidy is the defining genetic signature in 40-50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P = 0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P = 0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.
Collapse
Affiliation(s)
- W J Chng
- Division of Hematology-Oncology, Mayo Clinic Scottsdale, AZ 85259, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
|
41
|
Chng WJ, Price-Troska T, Van Wier S, Jacobus S, Blood E, Henderson K, Oken MM, Van Ness B, Greipp P, Fonseca R. Clinical and biological implication of defective p53 pathway in multiple myeloma (MM). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17516 Background: The p53 tumor suppressor is commonly inactivated by mutations. Even in tumors without mutations, there are defects in the response to p53 activation. In MM, the prognostic significance of p53 mutation is unknown, while there has been no systematic study of p53 function. We seek to address these issues in this study. Methods: p53 mutation was studied by conformation sensitive gel electrophoresis with primers encompassing exons 1 to 10 followed by sequencing of DNA fragments with altered electrophoretic pattern in newly diagnosed MM patients entered into ECOG E9486 trial where patients were randomized to receive variations of melphalan-based conventional chemotherapy (VBMCP). Fisher’s exact tests were used to compare variables between patients. Kaplan-Meier survival curves were compared using the log-rank test. To investigate p53 function, we analyzed the expression of p53, and 3 of its transcriptional targets, APAF1, p21 and MDM2, in a separate cohort of 15 normal plasma cells (PC), 14 MGUS, 13 smoldering myeloma (SMM) and 101 MM (73 new and 28 relapsed) from the Mayo Clinic who had gene expression profiling performed on the Affymetrix U133A chip (Santa Clara, Ca). Results: Two hundred and sixty-eight patients had enough materials for study and were included in the analysis. The prevalence of p53 mutation was 3% (n = 9). Five of the 9 patients (56%, p = 0.001) with mutations also had p53 deletion (studied by fluorescent in-situ hybridization) resulting in bi-allelic loss of p53. Soft tissue plasmacytomas (37% v 7%, p = 0.018), and among the common translocations, t(4;14) and t(14;16) (50% v 18%) were more common in patients with p53 mutations. Despite similar response to treatment, those with p53 mutation had very short OS (16.7 v 41.4 months, p < 0.001). There was induction of p53 expression in MGUS and SMM with concurrent induction of APAF1, p21 and MDM2 whereas loss of this pattern was frequent in MM (45% in new MM and 60% in relapse MM compared to 15% in MGUS/SMM (p = 0.03)). Conclusions: p53 mutations are relatively rare in newly diagnosed MM patients but portend a short survival. However, functional abnormalities of p53 are prevalent and may be important in progression from MGUS/SMM to MM. [Table: see text]
Collapse
Affiliation(s)
- W. J. Chng
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - T. Price-Troska
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - S. Van Wier
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - S. Jacobus
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - E. Blood
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - K. Henderson
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - M. M. Oken
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - B. Van Ness
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - P. Greipp
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| | - R. Fonseca
- Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Hubert H. Humphrey Cancer Center, Robbinsdale, MN; University of Minnesota, Minneapolis, MN
| |
Collapse
|
42
|
Clarizia S, Spada M, Panarello G, Cintorino D, Henderson K, Parrinello M, Carollo T, Nadalin S, Burgio G, Arcadipane A, Gridelli B. Pediatric liver transplantation: preliminary results at IsmeTT-Palermo. Transplant Proc 2006; 38:829-30. [PMID: 16647485 DOI: 10.1016/j.transproceed.2006.02.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
43
|
Cintorino D, Riva S, Spada M, Minervini M, Sonzogni A, Foglieni CS, Gruttadauria S, Verzaro R, Henderson K, Aricò M, Gridelli B. Corticosteroid-Free Immunosuppression in Pediatric Liver Transplantation: Safety and Efficacy After a Short-Term Follow-up. Transplant Proc 2006; 38:1099-100. [PMID: 16757276 DOI: 10.1016/j.transproceed.2006.02.147] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
BACKGROUND We report our results with the use of corticosteroid-free immunosuppression after pediatric liver transplantation, evaluating the efficiency and safety of this protocol in the early posttransplantation period. PATIENTS AND METHODS From July 2003 to October 2005, 34 liver transplantations were performed in 32 pediatric patients (19 boys, 13 girls) at our institution. Recipient median age was 5 years (range, 0.2-14 years), and median body weight was 10 kg (range, 4-49 kg). Twenty-seven patients received a graft from in situ split liver transplantation, 5 a whole graft. Twenty-nine children (90%) received an immunosuppressive therapy based on methylprednisolone IV bolus at reperfusion (10 mg/kg) plus tacrolimus given at an initial dose of 0.08 mg/kg/d and then adjusted to obtain whole blood trough levels of 10 to 15 ng/mL during the first 3 months and 5 to 10 ng/mL after the 3rd month; basiliximab was given on postoperative days 0 and 4. Biopsy-proven acute rejection episodes were treated by methylprednisone IV boluses. RESULTS After a median follow-up of 9 months (range, 1-27 months), the overall patient survival rate was 84% and graft survival rate was 79%. Three children (9%) died after their transplantations. Three (9%) experienced episodes of biopsy-proven acute rejection, always treated with IV steroid boluses. Mean RAI score was 4. One patient experienced PTLD that resolved with temporary reduction of immunosuppression. Cytomegalovirus infection rate was 14%. Sepsis occurred in 2 cases (6%). CONCLUSIONS Initial results with a steroid-free immunosuppressive protocol are encouraging, with low rates of acute rejection and infectious complications as in steroid-based protocols.
Collapse
Affiliation(s)
- D Cintorino
- Liver Transplantation Unit, Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione (IsMeTT), UPMC Italy, Palermo
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Cintorino D, Spada M, Gruttadauria S, Riva S, Luca A, Volpes R, Vizzini G, Arcadipane A, Henderson K, Verzaro R, Foglieni CS, Gridelli B. In Situ Split Liver Transplantation for Adult and Pediatric Recipients: An Answer to Organ Shortage. Transplant Proc 2006; 38:1096-8. [PMID: 16757275 DOI: 10.1016/j.transproceed.2006.02.146] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND We report our initial experience with in situ split liver transplantation (SLT) for adult and pediatric patients. PATIENTS AND METHODS From June 2003 to August 2005, 177 liver transplantations in 165 patients, 133 adults (81%) and 32 children (19%), were performed at our institution. Over this period, 45 liver transplantations (25%) were performed with an in situ split liver technique in 44 patients: 17 (39%) were adults and 27 (61%) children. All of the adult split liver recipients were transplanted with an extended right graft (ERG; segments I + IV-VIII), while pediatric recipients received in 23 cases a left lateral segment (LLS; segments II-III) and in 4 cases an ERG from a pediatric donor. The 45 split liver grafts (21 ERGs and 24 LLSs) were generated from 35 donors. In 10 cases we used both grafts generated with an in situ split procedure to transplant our patients, while in 25 cases the procurement procedure was performed in collaboration with other transplant centers. RESULTS After a median follow-up of 9 months (range, 1-27 months), the overall patient survival rate was 88% for adult patients and 82% for pediatric patients. Graft survivals were 88% and 79%, respectively. Two adult patients (12%) died from sepsis in the early postoperative period. Five children (18%) died after their transplantations. Only one pediatric recipient (2%) of primary SLT underwent retransplantation. Vascular complications were absent in adult recipients, whereas 4 arterial (14%) and 4 venous (14%) complications developed in the pediatric population. The incidence of biliary complications was 23% in adult and 18% in pediatric recipients. CONCLUSIONS The use of in situ SLT for adult and pediatric populations allowed us to expand the cadaveric donor pool, significantly eliminating pediatric waiting list mortality without penalizing the adult population.
Collapse
Affiliation(s)
- D Cintorino
- Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione (IsMeTT), University of Pittsburgh Medical Center, Palermo, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Henderson K, Kelkar H, Gutiérrez-Medina B, Li TC, Raizen MG. Experimental study of the role of atomic interactions on quantum transport. Phys Rev Lett 2006; 96:150401. [PMID: 16712132 DOI: 10.1103/physrevlett.96.150401] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2005] [Indexed: 05/09/2023]
Abstract
We report an experimental study of quantum transport for atoms confined in a periodic potential and compare between thermal and Bose-Einstein condensation (BEC) initial conditions. We observe ballistic transport for all values of well depth and initial conditions, and the measured expansion velocity for thermal atoms is in excellent agreement with a single-particle model. For weak wells, the expansion of the BEC is also in excellent agreement with single-particle theory, using an effective temperature. We observe a crossover to a new regime for the BEC case as the well depth is increased, indicating the importance of interactions on quantum transport.
Collapse
Affiliation(s)
- K Henderson
- Center for Nonlinear Dynamics and Department of Physics, The University of Texas at Austin, Austin, Texas 78712, USA
| | | | | | | | | |
Collapse
|
46
|
Chng WJ, Winkler JM, Greipp PR, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Ahmann GJ, Henderson K, Blood E, Oken MM, Hulbert A, Van Wier SA, Santana-Dávila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R. Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res 2005; 30:266-71. [PMID: 16111750 DOI: 10.1016/j.leukres.2005.07.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2005] [Revised: 07/07/2005] [Accepted: 07/12/2005] [Indexed: 10/25/2022]
Abstract
Hyperdiploid and non-hyperdiploid multiple myeloma represents distinct biological entities characterized by different patterns of genetic changes. We sought to determine whether ploidy category (non-hyperdiploid versus hyperdiploid) remains stable over time from diagnosis to progression. Of the 43 patients studied (39 by flow cytometry DNA index and 4 by a FISH-based index), only five (12%) altered their ploidy status at progression. In three of these patients, the change may possibly be attributable to technical artifacts because of the low absolute change in DNA index. For those who retain their ploidy subtypes, the DNA index change minimally (3.75+/-4.87%). It would appear that the initiating genetic events underlying hyperdiploid and non-hyperdiploid MM that marks them out as distinct entities continue to dominate and persist during disease evolution and progression.
Collapse
Affiliation(s)
- W J Chng
- Mayo Clinic Scottsdale, Comprehensive Cancer Center, Division of Haematology-Oncology, Johnson Research Building, Scottsdale, AZ 85259, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Kerridge I, Maguire J, Newby D, McNeill PM, Henry D, Hill S, Day R, Macdonald G, Stokes B, Henderson K. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. Intern Med J 2005; 35:206-10. [PMID: 15836497 DOI: 10.1111/j.1444-0903.2004.00799.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND There is extensive and varied interaction between the pharmaceutical industry and the medical profession. Most empirical research concerns contact between individual physicians and industry, and reflects North American experience. We sought to clarify the extent and nature of relationships between the pharmaceutical industry and Australian medical organizations. METHODS We administered questionnaires to 63 medical organizations concerned with clinical practice, continuing medical education or professional accreditation, or the political representation of medical professionals. RESULTS Survey instruments were received from 29 organizations, giving a response rate of 46%. Seventeen of these organizations (59%) had received support from one or more pharmaceutical company in the past financial year. Support was predominantly for annual conferences, with some support for continuing medical education, research, travel and library purchases. The majority of organizations had an academic journal or newsletter, and 10 (34%) accepted revenue from pharmaceutical advertising. Twenty organizations (72%) had policies or guidelines covering their relationship with industry. Few organizations indicated that they would be unable to continue their activities without pharmaceutical industry support. CONCLUSION These data indicate a high level of inter-action between the pharmaceutical industry and medical organizations in Australia. While most organizations have policies for guiding their relationship with industry, it is unclear whether these are effective in preventing conflicts of interest and maintaining public trust.
Collapse
Affiliation(s)
- I Kerridge
- Centre for Values, Ethics and the Law in Medicine, University of Sydney, Sydney, New South Wales 2006, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Krejsa C, Hughes S, Wagener F, Bannink K, Johnson B, Henderson K, Holly R, Sievers E, Rogge M. Enhancement of trastuzumab-mediated cellular cytotoxicity by interleukin-21. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Krejsa
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - S. Hughes
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - F. Wagener
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - K. Bannink
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - B. Johnson
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - K. Henderson
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - R. Holly
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - E. Sievers
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| | - M. Rogge
- ZymoGenetics, Inc., Seattle, WA; ZymoGenetics, Inc., Osaka, WA
| |
Collapse
|
49
|
Hughes SD, Krejsa C, Wagner F, Heffernan J, Henderson K, Roque R, Ponce R, Kindsvogel W, Sievers E, Rogge M. IL-21 enhancement of rituximab-mediated B cell depletion. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2568] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Flessner M, Choi J, Credit K, Henderson K, Vanpelt H, Deverkadra R, Nephrology D. 204 INTERSTITIAL HYPERTENSION PRESENTS A MAJOR CHALLENGE TO INTRAPERITONEAL DELIVERY OF THERAPEUTIC ANTIBODY TO METASTATIC OVCAR3 TUMORS IN NUDE RATS. J Investig Med 2004. [DOI: 10.1136/jim-52-suppl1-757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|